Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting.
Overall survival
Radio-oncological treatment
Recurrent brain metastasis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Mar 2022
15 Mar 2022
Historique:
received:
22
03
2021
accepted:
19
02
2022
entrez:
16
3
2022
pubmed:
17
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Treatment decision for recurrent symptomatic brain metastases (BM) is challenging with scarce data regarding surgical resection. We therefore evaluated the efficacy of surgery for pretreated, recurrent BM in a comprehensive multidisciplinary treatment setting. In a retrospective single center study, patients were analyzed, who underwent surgical resection of recurrent BM between 2007 and 2019. Intracranial event-free survival (EFS) and overall survival (OS) were evaluated by Kaplan-Maier and Cox regression analysis. We included 107 patients with different primary tumor entities and individual previous treatment for BM. Primary tumors comprised non-small cell lung cancer (NSCLC) (37.4%), breast cancer (19.6%), melanoma (13.1%), gastro-intestinal cancer (10.3%) and other, rare entities (19.6%). The number of previous treatments of BM ranged from one to four; the adjuvant treatment modalities comprised: none, focal or whole brain radiotherapy, brachytherapy and radiosurgery. The median pre-operative Karnofsky Performance Score (KPS) was 70% (range 40-100) and improved to 80% (range 0-100) after surgery. The complication rate was 26.2% and two patients died during the perioperative period. Sixty-seven (62.6%) patients received postoperative local radio-oncologic and/or systemic therapy. Median postoperative EFS and OS were 7.1 (95%CI 5.8-8.2) and 11.1 (95%CI 8.4-13.6) months, respectively. The clinical status (postoperative KPS ≥ 70 (HR 0.27 95%CI 0.16-0.46; p < 0.001) remained the only independent factor for survival in multivariate analysis. Surgical resection of recurrent BM may improve the clinical status and thus OS but is associated with a high complication rate; therefore a very careful patient selection is crucial.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment decision for recurrent symptomatic brain metastases (BM) is challenging with scarce data regarding surgical resection. We therefore evaluated the efficacy of surgery for pretreated, recurrent BM in a comprehensive multidisciplinary treatment setting.
METHODS
METHODS
In a retrospective single center study, patients were analyzed, who underwent surgical resection of recurrent BM between 2007 and 2019. Intracranial event-free survival (EFS) and overall survival (OS) were evaluated by Kaplan-Maier and Cox regression analysis.
RESULTS
RESULTS
We included 107 patients with different primary tumor entities and individual previous treatment for BM. Primary tumors comprised non-small cell lung cancer (NSCLC) (37.4%), breast cancer (19.6%), melanoma (13.1%), gastro-intestinal cancer (10.3%) and other, rare entities (19.6%). The number of previous treatments of BM ranged from one to four; the adjuvant treatment modalities comprised: none, focal or whole brain radiotherapy, brachytherapy and radiosurgery. The median pre-operative Karnofsky Performance Score (KPS) was 70% (range 40-100) and improved to 80% (range 0-100) after surgery. The complication rate was 26.2% and two patients died during the perioperative period. Sixty-seven (62.6%) patients received postoperative local radio-oncologic and/or systemic therapy. Median postoperative EFS and OS were 7.1 (95%CI 5.8-8.2) and 11.1 (95%CI 8.4-13.6) months, respectively. The clinical status (postoperative KPS ≥ 70 (HR 0.27 95%CI 0.16-0.46; p < 0.001) remained the only independent factor for survival in multivariate analysis.
CONCLUSIONS
CONCLUSIONS
Surgical resection of recurrent BM may improve the clinical status and thus OS but is associated with a high complication rate; therefore a very careful patient selection is crucial.
Identifiants
pubmed: 35291972
doi: 10.1186/s12885-022-09317-6
pii: 10.1186/s12885-022-09317-6
pmc: PMC8922794
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
275Informations de copyright
© 2022. The Author(s).
Références
Curr Treat Options Oncol. 2016 Sep;17(9):46
pubmed: 27447703
Neurosurg Rev. 2005 Apr;28(2):115-9
pubmed: 15609059
Support Care Cancer. 2016 Aug;24(8):3669-76
pubmed: 27260018
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
pubmed: 9128946
J Neurooncol. 2021 Feb;151(3):429-442
pubmed: 33611709
J Neurosurg. 2005 Feb;102(2):209-15
pubmed: 15739546
J Neurosurg. 2009 Oct;111(4):825-31
pubmed: 19425892
Acta Neurochir (Wien). 2013 Oct;155(10):1823-32
pubmed: 23913109
Cancer Med. 2019 Nov;8(16):6809-6831
pubmed: 31568689
J Neurosurg. 1995 Oct;83(4):600-4
pubmed: 7674007
J Thorac Cardiovasc Surg. 2002 Jul;124(1):113-22
pubmed: 12091816
Ecancermedicalscience. 2013 Apr 18;7:306
pubmed: 23653671
Neuro Oncol. 2017 Jan;19(1):i1-i24
pubmed: 28031389
Nat Rev Cancer. 2011 May;11(5):352-63
pubmed: 21472002
Neurosurgery. 2011 May;68(5):1209-18; discussion 1218-9
pubmed: 21273930
Am Soc Clin Oncol Educ Book. 2016;35:67-73
pubmed: 27249687
Cancer Med. 2020 Oct;9(20):7503-7510
pubmed: 32858763
Neurosurgery. 2019 Mar 1;84(3):550-552
pubmed: 30629218
J Neurooncol. 2010 Jan;96(1):85-96
pubmed: 19957016
J Neurooncol. 2010 Jan;96(1):33-43
pubmed: 19960230
Acta Neurochir (Wien). 2012 Nov;154(11):1981-6
pubmed: 22875595
J Neurooncol. 2019 Dec;145(3):551-559
pubmed: 31667732